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Abstract
Autism spectrum disorders (ASD) are a group of neurodevelopmental conditions whose incidence
is reaching epidemic proportions, afflicting approximately 1 in 166 children. Autistic disorder, or
autism is the most common form of ASD. Although several neurophysiological alterations have
been associated with autism, immune abnormalities and neural hypoperfusion appear to be broadly
consistent. These appear to be causative since correlation of altered inflammatory responses, and
hypoperfusion with symptology is reported. Mesenchymal stem cells (MSC) are in late phases of
clinical development for treatment of graft versus host disease and Crohn's Disease, two conditions
of immune dysregulation. Cord blood CD34+ cells are known to be potent angiogenic stimulators,
having demonstrated positive effects in not only peripheral ischemia, but also in models of cerebral
ischemia. Additionally, anecdotal clinical cases have reported responses in autistic children
receiving cord blood CD34+ cells. We propose the combined use of MSC and cord blood
CD34+cells may be useful in the treatment of autism.
Background
Autism spectrum disorders (ASD) are reaching epidemic
proportions, believed to affect approximately 1 in 166
children. Autism, Asperger's syndrome, Rett's disorder,
and childhood disintegrae disorder are all encompassed
by the term ASD. Autism is the most prevalent ASD, char-
acterized by abnormalities in social interaction, impaired
verbal and nonverbal communication, and repetitive,
obsessive behavior. Autism may vary in severity from mild
to disabling and is believed to arise from genetic and envi-
ronmental factors. While symptomology of autism may
be noted by caregivers around 12–18 months [1], defini-
tive diagnosis generally occurs around 24–36 months,
however in some cases diagnosis may be made into adult-
hood [2]. Determination of autism is performed using the
DSM-IV-TR, or other questionnaires and tests. Children
with autism appear withdrawn, self-occupied, and distant.
Inflexibility in terms of learning from experiences and
modifying patterns to integrate into new environments is
characteristic of autism. Depending on degree of severity,
some children with autism may develop into independent
adults with full time employment and self sufficiency;
however this is seldom the case.
Current treatments for autism can divided into behavio-
ral, nutritional and medical approaches, although no
clear golden standard approach exists. Behavioral inter-
ventions usually include activities designed to encourage
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social interaction, communication, awareness of self, and
increase attention. Nutritional interventions aim to
restrict allergy-associated dietary components, as well as
to supplement minerals or vitamins that may be lacking.
Medical interventions usually treat specific activities asso-
ciated with autism. For example, serotonin reuptake
inhibitors (SSRI's) such as fluoxetine, fluvoxamine, sertra-
line, and clomipramine, are used for treatment of anxiety
and depression. Some studies have shown that SSRI's also
have the added benefit of increasing social interaction and
inhibiting repetitive behavior. Typical antipsychotic drugs
such as thioridazine, fluphenazine, chlorpromazine, and
haloperidol have been showed to decrease behavioral
abnormalities in autism. Atypical antipsychotics such as
risperidone, olanzapine and ziprasidone have also dem-
onstrated beneficial effect at ameliorating behavioral
problems. Autism associated seizures are mainly treated
by administration of anticonvulsants such as car-
bamazepine, lamotrigine, topiramate, and valproic acid.
Attention deficient/hyperactivity is treated by agents such
as methylphenidate (Ritalin®).
Currently, numerous clinical trials are being conducted
with interventions ranging from hyperbaric oxygen, to
administration of zinc, to drugs exhibiting anti-inflamma-
tory properties. Unfortunately, no clear understanding of
autism's pathogenic mechanisms exists, and as a result
numerous strategies are being attempted with varying
degrees of success. In this paper we examine two patholo-
gies associated with autism – hypoperfusion to the brain
and immune dysregulation – and propose a novel treat-
ment: the administration of CD34+ umbilical cord cells
and mesenchymal cells.
Hypoperfusion of brain in autism
Children with autism have been consistently shown to
have impaired, or subnormal CNS circulation, as well as
resulting hypoxia. Defects include basal hypoperfusion
[3], and decreased perfusion in response to stimuli that
under normal circumstances upregulates perfusion [4]. In
numerous studies the areas affected by hypoperfusion
seem to correlate with regions of the brain that are respon-
sible for functionalities that are abnormal in autism. For
example, specific temporal lobe areas associated with face
recognition [5], social interaction [6], and language com-
prehension [7], have been demonstrated to be hypoper-
fused in autistic but not control children.
The question of cause versus effect is important. If tempo-
ral lobe ischemia is not causative but only a symptom of
an underlying process, then targeting this pathology may
be non-productive from the therapeutic perspective. How-
ever this appears not to be the case. It is evident that the
degree of hypoperfusion and resulting hypoxia correlates
with the severity of autism symptoms. For example, statis-
tically significant inverse correlation has been demon-
strated between extent of hypoxia and IQ [8]. Supporting
a causative effect of hypoperfusion to autism develop-
ment, Bachavelier et al reviewed numerous experimental
reports of primate and other animal studies in which
damage causing hypoperfusion of temporal areas was
associated with onset of autism-like disorders [9]. It is also
known that after removal or damage of the amygdala, hip-
pocampus, or other temporal structures induces either
permanent or transient autistic-like characteristics such as
unexpressive faces, little eye contact, and motor stereotyp-
ies occurs. Clinically, temporal lobe damage by viral and
other means has been implicated in development of
autism both in adults [10], and children [11-14].
Evidence suggests that hypoperfusion and resulting
hypoxia is intimately associated with autism, however the
next important question is whether reversion of this
hypoxia can positively influence autism. In autism the
associated hypoxia is not predominantly apoptotic or
necrotic to temporal neurons but associated with altered
function [15]. Hypoperfusion may contribute to defects
not only by induction of hypoxia but also allowing for
abnormal metabolite or neurotransmitter accumulation.
This is one of the reasons why glutamate toxicity has been
implicated in autism [16] and a clinical trial at reversing
this using the inhibitor of glutamate toxicity, Riluzole, is
currently in progress [17]. Conceptually the augmentation
of perfusion through stimulation of angiogenesis should
allow for metabolite clearance and restoration of func-
tionality. Although not well defined, cell death may also
be occurring in various CNS components of autistic chil-
dren. If this were the case, it is possible that neural regen-
eration can be stimulated through entry of neuronal
progenitor cells into cell cycle and subsequent differentia-
tion. Ample evidence of neural regeneration exists in areas
ranging from stroke [18], to subarachinoidal hemorrhage
[19,20], to neural damage as a result of congenital errors
of metabolism [21]. Theoretically, it is conceivable that
reversing hypoxia may lead to activation of self-repair
mechanisms. Such neural proliferation is seen after reper-
fusion in numerous animal models of cerebral ischemia
[22-24]. The concept of increasing oxygen to the autistic
brain through various means such as hyperbaric medicine
is currently being tested in 2 independent clinical trials in
the US [25,26]. However, to our knowledge, the use of cell
therapy to stimulate angiogenesis has not been widely-
used for the treatment of autism.
Immune deregulation in autism
The fundamental interplay between the nervous system
and the immune system cannot be understated. Philo-
sophically, the characteristics of self/nonself recognition,
specificity, and memory are only shared by the immune
system and the nervous system. Physically, every immuneJournal of Translational Medicine 2007, 5:30 http://www.translational-medicine.com/content/5/1/30
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organ is innervated and bi-directional communication
between neural and immune system cells has been estab-
lished in numerous physiological systems. In autism, sev-
eral immunological abnormalities have been detected
both in the peripheral and the central nervous systems.
Astroglial cells, or astrocytes, surround various portions of
the cerebral endothelium and play a critical role in regu-
lating perfusion [27,28], and blood brain barrier function
[29]. Astrocytes are capable of mediating several immuno-
logical/inflammatory effects. Expression of various toll
like receptors (TLR) on astrocytes endows the ability to
recognize not only bacterial and viral signals but also
endogenous "danger" signals such as heat shock proteins,
fibrinogen degradation products, and free DNA [30].
Physiologically, astrocytes play an important protective
role against infection, generating inflammatory cytokines
such as TNF-alpha, IL-1beta, and IL-6 [31]. Through secre-
tion of various chemokines such as CXCL10, CCL2 and
BAFF, astrocytes play an important role in shaping adap-
tive immune responses in the CNS [32]. Astrocytes have
antigen presenting capabilities and have been demon-
strated to activate T and B cell responses against exoge-
nous and endogenous antigens [33,34]. Although
astrocytes play a critical role against CNS infection, these
cells also have potential to cause damage to the host when
functioning in an aberrant manner. For example, various
neurological diseases are associated with astrocyte over-
production of inflammatory agents, which causes neural
malfunction or death. In amyotrophic lateral sclerosis
(ALS), astrocyte secretion of a soluble neurotoxic sub-
stance has been demonstrated to be involved in disease
progression [35,36]. Astrocyte hyperactivation has been
demonstrated in this disease by imaging, as well as
autopsy studies [37-39]. In multiple sclerosis, astrocytes
play a key role in maintaining autoreactive responses and
pathological plaque formation [40,41]. In stroke, acti-
vated astrocytes contribute to opening of the blood brain
barrier [42], as well as secrete various neurotoxic sub-
stances that contribute to post infarct neural damage
[43,44].
Vargas et al compared brain autopsy samples from 11
autistic children with 7 age-matched controls. They dem-
onstrated an active neuroinflammatory process in the cer-
ebral cortex, white matter, and notably in cerebellum of
autistic patients both by immunohistochemistry and
morphology. Importantly, astrocyte production of
inflammatory cytokines was observed, including produc-
tion of cytokines known to affect various neuronal func-
tions such as TNF-alpha and MCP-1. CSF samples from
living autism patients but not controls also displayed
upregulated inflammatory cytokines as demonstrated by
ELISA [45]. The potent effects of inflammatory cytokines
on neurological function cannot be underestimated. For
example, patients receiving systemic IFN-gamma therapy
for cancer, even though theoretically the protein should
not cross the blood brain barrier, report numerous cogni-
tive and neurological abnormalities [46,47]. In fact, IFN-
gamma, one of the products of activated astrocytes [46],
has been detected at elevated levels in the plasma of chil-
dren with autism [48,49]. Mechanistically, inflammatory
mediators mediate alteration of neurological function
through a wide variety of different pathways, either
directly altering neuron activity or indirectly. For example,
the common neurotoxin used in models of Parkinson's
Disease, MPTP is believed to mediate its activity through
activation of IFN-gamma production, leading to direct
killing of dopaminergic neurons in the substantia nigra.
This is evidenced by reduced MPTP neuronal toxicity in
IFN-gamma knockout mice or by addition of blocking
antibodies to IFN-gamma [50]. In terms of indirect effects
of IFN-gamma, it is known that this cytokine activates the
enzyme 2,3-indolaminedeoxygenase, leading to genera-
tion of small molecule neurotoxins such as the kynure-
nine metabolites 3OH-kynurenine and quinolinic acid
which have been implicated in dementias associated with
chronic inflammatory states [51,52].
T cell and B cell abnormalities have been reported system-
ically in autistic children. These have included systemic T
cell lymphopenia, weak proliferative responses to
mitogens, and deranged cytokine production [53,54]. At
face value, lymphopenia would suggest general immune
deficiency and as a result little inflammation, however,
recent studies have demonstrated that almost all autoim-
mune diseases are associated with a state of generalized
lymphopenia (reviewed by Marleau and Sarvetnick [55]).
Autoimmune-like pathophysiology appears to be preva-
lent in autism and several lines of reasoning suggest it may
be causative. Firstly, numerous types of autoantibodies
have been detected in children with autism but not in
healthy or mentally challenged controls. These include
antibodies to myelin basic protein [56], brain extracts
[57,58], Purkinje cells and gliadin extracted peptides [59],
neutrophic factors [60,61], and neuron-axon filament and
glial fibrillary acidic protein [61]. Secondly, family mem-
bers of autistic children have a higher predisposition
towards autoimmunity compared to control populations
[62,63]. Hinting at genetic mechanisms are observations
that specific HLA haplotypes seem to associate with
autism [64,65]. Another genetic characteristic associated
with autism is a null allele for the complement compo-
nent C4b [66]. Both HLA haplotypes as well as comple-
ment component gene polymorphisms have been
strongly associated with autoimmunity [67-69]. It is
known that autoimmune animals have altered cognitive
ability and several neurological abnormalities [70].
Thirdly, autism has been associated with a peculiar
autoimmune-like syndrome that is still relatively unde-Journal of Translational Medicine 2007, 5:30 http://www.translational-medicine.com/content/5/1/30
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fined. Mucosal lesions in the form of chronic ileocolonic
lymphoid nodular hyperplasia characterized by lym-
phocyte infiltration, complement deposition, and
cytokine production have been described uniquely to
children with autism but not healthy controls or cerebral
palsy patients [71]. This inflammatory condition is associ-
ated not only with lesions on the intestinal wall, but also
in the upper GI tract. Although several characteristics of
this condition are shared with Crohn's Disease, one
unique aspect is eosinophilic infiltrate, which seems to be
associated with dietary habits of the patient [72]. Systemic
manifestation of the immune deregulation/chronic
inflammatory condition are observed through elevated
levels of inflammatory cytokines such as IFN-gamma [73],
IL-12 [74], and TNF-alpha [75]. Indication that a relevant
inflammatory response is ongoing is provided by observa-
tion that the macrophage product neopterin is observed
elevated in children with autism [76]. Inhibited produc-
tion of anti-inflammatory cytokines such as IL-10 [77]
and TGF-beta [78] has also been observed in children with
autism, thus suggesting not only augmentation of inflam-
matory processes but also deficiency of natural feedback
inhibitor mechanisms.
The systemic effects of a chronic inflammatory process in
the periphery may result in production of soluble factors
such as quinilonic acid, which have neurotoxin activity.
Ability of cellular immune deregulation to affect neural
function can occur independent of cell trafficking, as was
demonstrated in animal studies in which T cell depletion
was associated with cognitive loss of function that was
reversible through T cell repletion [79]. Localized inflam-
mation and pathological astrocyte activation has been
directly demonstrated to be associated with pathogenesis
in autism. Clinical trials of inflammatory drugs have dem-
onstrated varying degrees of success. For example, in an
open labeled study of the anti-inflammatory PPAR-
gamma agonist pioglitozone in 25 children, 75% reported
responses on the aberrant behavior checklist [80]. Other
interventions aimed at reducing inflammation such as
intravenous immunoglobulin administration reported
inconsistent results, however a minor subset did respond
significantly [81,82]. Clinical trials are currently using
drugs off-label for treatment of autism through inhibiting
inflammation such as minocycline [83], n-acetylcysteine
[84], or ascorbic acid and zinc [85]. Despite the desire to
correct immune deregulation/chronic inflammation in
autism, to date, no approach has been successful.
Treatment of hypoperfusion defect by umbilical 
cord blood CD34+ stem cell administration
Therapeutic angiogenesis, the induction of new blood ves-
sels from preexisting arteries for overcoming ischemia, has
been experimentally demonstrated in peripheral artery
disease [86], myocardial ischemia [87], and stroke [88].
Angiogenesis is induced through the formation of collat-
eral vessels and has been observed in hypoperfused tis-
sues. This process is believed to be coordinated by the
oxygen sensing transcription factor hypoxia inducible fac-
tor-1 (HIF-1). During conditions of low oxygen tension,
various components of the transcription factor dimerize
and coordinately translocate into the nucleus causing
upregulation of numerous cytokines and proteins associ-
ated with angiogenesis such as SDF-1, VEGF, FGF, and
matrix metalloproteases [89]. The potency of tissue
ischemia stimulating angiogenesis is seen in patients after
myocardial infarction in which bone marrow angiogenic
stem cells mobilize into systemic circulating in response
to ischemia induced chemotactic factors [90]. The ang-
iogenic response has also been demonstrated to occur
after cerebral ischemia in the form of stroke and is
believed to be fundamental in neurological recovery [91].
For example, in models of middle cerebral artery occlu-
sion, endogenous angiogenesis occurs which is also
involved in triggering migration of neural stem cells into
damaged area that participate in neuroregeneration [92].
The association between neural angiogenesis and neuro-
genesis after brain damage is not only temporally-linked
but also connected by common mediators, for example,
SDF-1 secreted in response to hypoxia also induces migra-
tion of neural progenitors [92]. Angiogenic factors such as
VEGF and angiopoietin have been implicated in post
ischemia neurogenesis [93].
While recovery after cerebral ischemia occurs to some
extent without intervention, this recovery is can be lim-
ited. Methods to enhance angiogenesis and as a result
neurogenesis are numerous and have utilized approaches
that upregulate endogenous production of reparative fac-
tors, as well as administration of exogenous agents. For
example, administration of exogenous cytokines such as
FGF-2 [94], erythropoietin [95], and G-CSF [96], has been
performed clinically to accelerate healing with varying
degrees of success.
A promising method of increasing angiogenesis in situa-
tions of ischemia is administration of cells with potential
to produce angiogenic factors and the capacity to differen-
tiate into endothelial cells themselves. Accordingly, the
use of CD34+ stem cells has been previously proposed as
an alternative to growth factor administration [97]. Ther-
apeutic administration of bone marrow derived CD34+
cells has produced promising results in the treatment of
end-stage myocardial ischemia [98], as well as a type of
advanced peripheral artery disease called critical limb
ischemia [99]. Additionally, autologous peripheral blood
CD34+ cells have also been used clinically with induction
of therapeutic angiogenesis [100]. Of angiogenesis stimu-
lating cell sources, cord blood seems to possess CD34+
cells with highest activity in terms of proliferation,Journal of Translational Medicine 2007, 5:30 http://www.translational-medicine.com/content/5/1/30
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cytokine production, as well as endothelial differentiation
[101,102].
Cord blood has been used successfully for stimulation of
angiogenesis in various models of ischemia. In one report,
the CD34+, CD11b+ fraction, which is approximately less
than half of the CD34+ fraction of cord blood was dem-
onstrated to possess the ability to differentiate into
endothelial cells [102]. In another report, VEGF-R3+,
CD34+ cells demonstrated the ability to differentiate into
endothelial cells and were able to be expanded 40-fold
expansion. The concentration of this potential endothe-
lial progenitor fraction in cord blood CD34+ cells is
approximately tenfold higher as compared to bone mar-
row CD34+ cells (1.9% +/- 0.8% compared to 0.2% +/-
0.1%) [103]. Administration of cord blood CD34+ cells
into immune compromised mice that underwent middle
cerebral artery ligation reduced neurological deficits and
induce neuroregeneration, in part through secretion of
angiogenic factors [104]. Several studies have confirmed
that systemic administration of cord blood cells is suffi-
cient to induce neuroregeneration [105-107]. Given the
potency of cord blood CD34+ cells to induce angiogenesis
in areas of cerebral hypoperfusion, we propose that this
cell type may be particularly useful for the treatment of
autism, in which ischemia is milder than stroke induced
ischemia, and as a result the level of angiogenesis needed
is theoretically lower. However at face value, several con-
siderations have to be dealt with. Firstly, cord blood con-
tains a relatively low number of CD34+ cells for clinical
use. Secondly, very few patients have access to autologous
cord blood; therefore allogeneic cord blood CD34+ cells
are needed if this therapy is to be made available for wide-
spread use. There is a belief that allogeneic cord blood
cells can not be used without immune suppression to
avoid host versus graft destruction of the cells.
Numerous laboratories are currently attempting to
expand cord blood CD34+ cells, achieving varying degrees
of success. Expansion methods typically involve adminis-
tration of cytokines, and or feeder cell layers [108-110].
The authors have developed a CD34+ expansion protocol
that yields up to 60-fold expansion with limited cell dif-
ferentiation. This expansion method involves numerous
growth factors and conditioned medium, however is per-
formed under serum free conditions (manuscript in prep-
aration). Currently over 100 patients have been treated by
one of the authors (FS) with expanded CD34+ cells under
local ethical approval with varying degrees of success.
Since other groups are also generating CD34+ expansion
technologies, we do not anticipate number of CD34+ cells
to be a problem.
Safety concerns regarding allogeneic CD34+ cells are
divided into fears of graft versus host reactions, as well as
host versus graft. The authors of the current paper have
recently published a detailed rationale for why adminis-
tration of cord blood cells is feasible in absence of
immune suppression [111]. Essentially, GVHD occurs in
the context of lymphopenia caused by bone marrow abla-
tion. Administration of cord blood has been reported in
over 500 patients without a single one suffering GVHD if
no immune suppression was used [112-115]. Although
host versus graft may conceptually cause immune medi-
ated clearing of cord blood cells, efficacy of cord blood
cells in absence of immune suppression has also been
reported [116-118]. Accordingly, we believe that systemic
administration of expanded cord blood derived CD34+
cells may be a potent tool for generation of neoangiogen-
esis in the autistic brain.
Immune modulation by mesenchymal stem cells
The treatment of immune deregulation in autism is
expected to not only cause amelioration of intestinal and
systemic symptomology, but also to profoundly influence
neurological function. Reports exist of temporary neuro-
logical improvement by decreasing intestinal inflamma-
tion through either antibiotic administration [119] or
dietary changes [120]. Although, as previously discussed,
some anti-inflammatory treatments have yielded benefi-
cial effects, no clinical agent has been developed that can
profoundly suppress inflammation at the level of the fun-
damental immune abnormality. We believe mesenchymal
stem cell administration may be used for this purpose.
This cell type, in allogeneic form, is currently in Phase III
clinical studies for Crohn's disease and Phase II results
have demonstrated profound improvement [121].
Mesenchymal stem cells are classically defined as "forma-
tive pluripotential blast cells found inter alia in bone mar-
row, blood, dermis and periosteum that are capable of
differentiating into any of the specific types of mesenchy-
mal or connective tissues. These cells are routinely gener-
ated by culture of bone marrow in various culture media
and collection of the adherent cell population. This
expansion technique is sometimes used in combination
with selection procedures for markers described above to
generate a pure population of stem cells. An important
characteristic of mesenchymal stem cells is their ability to
constitutively secrete immune inhibitory factors such as
IL-10 and TGF-b while maintaining ability to present anti-
gens to T cells [122,123]. This is believed to further allow
inhibition of immunity in an antigen specific manner, as
well as to allow the use of such cells in an allogeneic fash-
ion without fear of immune-mediated rejection. Antigen-
specific immune suppression is believed to allow these
cells to shut off autoimmune processes. Further under-
standing of the immune inhibitory effects of mesenchy-
mal stem cells comes from the fact that during T cell
activation, two general signals are required for the T cell inJournal of Translational Medicine 2007, 5:30 http://www.translational-medicine.com/content/5/1/30
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order to mount a productive immune response, the first
signal is recognition of antigen, and the second is recogni-
tion of costimulatory or coinhibitory signals. Mesenchy-
mal cells present antigens to T cells but provide a
coinhibitory signal instead of a co-stimulatory signal, thus
specifically inhibiting T cells that recognize them, and
other cells expressing similar antigens. Supporting this
concept, it was demonstrated in a murine model that mes-
enchymal stem cell transplantation leads to permanent
donor-specific immunotolerance in allogeneic hosts and
results in long-term allogeneic skin graft acceptance [124].
Other studies have shown that mesenchymal stem cells
are inherently immunosuppressive through production of
PGE-2, interleukin-10 and expression of the tryptophan
catabolizing enzyme indoleamine 2,3,-dioxygenase as
well as Galectin-1 [125,126].
These stem cells also have the ability to non-specifically
modulate the immune response through the suppression
of dendritic cell maturation and antigen presenting abili-
ties [127,128]. Immune suppressive activity is not
dependent on prolonged culture of mesenchymal stem
cells since functional induction of allogeneic T cell apop-
tosis was also demonstrated using freshly isolated, irradi-
ated, mesenchymal stem cells [129]. Others have also
demonstrated that mesenchymal stem cells have the abil-
ity to preferentially induce expansion of antigen specific T
regulatory cells with the CD4+ CD25+ phenotype [130].
Supporting the potential clinical utility of such cells, it
was previously demonstrated that administration of mes-
enchymal stem cells inhibits antigen specific T cell
responses in the murine model of multiple sclerosis,
experimental autoimmune encephalomyelitis, leading to
prevention and/or regression of pathology [131]. Safety of
infusing mesenchymal stem cells was illustrated in studies
administering 1–2.2 × 106 cells/kg in order to enhance
engraftment of autologous bone marrow cell. No adverse
events were associated with infusion, although level of
engraftment remained to be analyzed in randomized tri-
als [132]. The ability of mesenchymal stem cells on one
hand to suppress pathological immune responses but on
the other hand to stimulate hematopoiesis leads to the
possibility that these cells may also be useful for treatment
of the defect in T cell numbers associated with autism.
Practical clinical entry
We propose a Phase I/II open labeled study investigating
combination of cord blood expanded CD34+ cells
together with mesenchymal stem cells for the treatment of
autism. Such a trial would utilize several classical instru-
ments of autism assessment such as the Aberrant Behavior
Checklist and the Vineland Adaptive Behavior Scale
(VABS) for assessment of symptomatic effect. Objective
measurements of temporal lobe hypoperfusion, intestinal
lymphoid hypertrophy, immunological markers and
markers of hypoxia will be included. In order to initiate
such an investigation, specific inclusion/exclusion criteria
will be developed taking into account a population most
likely to benefit from such an intervention. Criteria of par-
ticular interest would include defined hypoxia areas, as
well as frank clinical manifestations of inflammatory
intestinal disease. Markers of inflammatory processes may
be used as part of the inclusion criteria, for example, ele-
vation of C-reactive protein, or serum levels of TNF-alpha,
IL-1, or IL-6 in order to specifically identify patients in
whom the anti-inflammatory aspects of stem cell therapy
would benefit [133,134]. More stringent criteria would
include restricting the study to only patients in which T
cell abnormalities are present such as ex vivo hypersecre-
tion of interferon gamma upon anti-CD3/CD28 stimula-
tion [135], as well as deficient production of immune
inhibitory cytokines such as IL-10 [77] and TGF-beta [78].
One of the authors (FS) has utilized both CD34+ and
mesenchymal stem cells clinically for treatment of various
diseases. In some case reports, the combination of CD34+
and mesenchymal stem cells was noted to induce syner-
gistic effects in neurological diseases, although the
number of patients are far too low to draw any conclu-
sions. We propose to conduct this study based on the pre-
vious experiences of our group in this field, as well as
numerous other groups that have generated anecdotal evi-
dence of stem cell therapy for autism but have not pub-
lished in conventional journals. We believe that through
development of a potent clinical study with appropriate
endpoints, much will be learned about the pathophysiol-
ogy of autism regardless of trial outcome.
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